Seasonal Influenza Vaccine Market in Asia - Pacific Region - Threat of Pandemic Influenza and Increasing Vaccination Coverage to Drive Growth

GBI Research, January 2011, Pages: 114

Seasonal Influenza Vaccine Market in Asia - Pacific Region - Threat of Pandemic Influenza and Increasing Vaccination Coverage to Drive Growth

Summary

GBI Research, the leading business intelligence provider has released its latest research “Seasonal Influenza Vaccine Market in Asia-Pacific Region-Threat of Pandemic Influenza and Increasing Vaccination Coverage to Drive Growth” which essentially provides insights on seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2016. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Australia, New Zealand, Taiwan, Philippines, Hong Kong and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also includes insights into the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines. The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented.

Scope

The scope of this report includes:
- Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Australia, New Zealand, Taiwan, Philippines, Malaysia, Hong Kong and Singapore.
- Market forecasts for the seasonal influenza vaccines until 2016
- Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share.
- Key drivers and restraints that have created significant impact on the market.
- Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region
- Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies, AdImmune and Crucell.
- Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2010 in the seasonal influenza vaccine market.

Reasons to buy

The report will aid business development and marketing executives strategizing their product launches:
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficacy and better safety.

1 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Introduction 11
2.1 Influenza 11
2.2 GBI Research Report Guidance 12
3 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Market Overview 13
3.1 Production Cycle for the Seasonal Influenza Vaccines 13
3.2 The Asia-Pacific Region Seasonal Influenza Vaccine Market 13
3.3 Revenue Forecasts for the Seasonal Influenza Vaccine Market 14
3.4 Geographical Segmentation 15
4 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Geographical Landscape 16
4.1 Revenue Analysis by Geography 16
4.2 Australia 17
4.2.1 Vaccination Pattern 17
4.2.2 Cost of Vaccine 21
4.2.3 Total Revenue 22
4.3 New Zealand 24
4.3.1 Vaccination Pattern 24
4.3.2 Cost of Vaccine 28
4.3.3 Total Revenue 28
4.3.4 Major Players by Market Share 30
4.4 Taiwan 31
4.4.1 Vaccination Pattern 31
4.4.2 Cost of Vaccine 35
4.4.3 Total Revenue 35
4.4.4 Major Players by Market Share 37
4.5 Philippines 38
4.5.1 Vaccination Pattern 38
4.5.2 Cost of Vaccine 42
4.5.3 Total Revenue 42
4.5.4 Major Players by Market Share 44
4.6 Malaysia 45
4.6.1 Vaccination Pattern 45
4.6.2 Cost of Vaccine 48
4.6.3 Total Revenue 49
4.6.4 Major Players by Market Share 51
4.7 Hong Kong 52
4.7.1 Vaccination Pattern 52
4.7.2 Cost of Vaccine 55
4.7.3 Total Revenue 56
4.7.4 Major Players by Market Share 58
4.8 Singapore 59
4.8.1 Vaccination Pattern 59
4.8.2 Cost of Vaccine 63
4.8.3 Total Revenue 63
4.8.4 Major Players by Market Share 65
5 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Drivers and Restraints 66
5.1 Drivers for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region 66
5.1.1 Threat of Pandemic Influenza 67
5.1.2 Increasing Vaccination Coverage for Seasonal Influenza Vaccines 69
5.1.3 Emergence of Novel Production Technologies and Vaccines 70
5.1.4 Population Growth 71
5.1.5 Economic Reasons 71
5.2 Restraints for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region 72
5.2.1 Entry Barriers in the Seasonal Influenza Vaccine Market 72
5.2.2 Variable Demand 72
5.2.3 Limited Production Capacity 72
5.3 Australia 73
5.3.1 Drivers 73
5.3.2 Restraints 73
5.4 New Zealand 73
5.4.1 Drivers 73
5.4.2 Restraints 74
5.5 Taiwan 74
5.5.1 Drivers 74
5.5.2 Restraints 74
5.6 Philippines 74
5.6.1 Drivers 74
5.6.2 Restraints 75
5.7 Malaysia 75
5.7.1 Drivers 75
5.7.2 Restraints 75
5.8 Hong Kong 76
5.8.1 Drivers 76
5.8.2 Restraints 76
5.9 Singapore 76
5.9.1 Drivers 76
5.9.2 Restraints 76
6 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Regulatory Landscape 77
6.1 Registration Process and Regulations in Australia 77
6.2 Registration Process and Regulations in New Zealand 79
6.3 Registration Process and Regulations in Taiwan 83
6.4 Registration Process and Regulations in the Philippines 85
6.5 Registration Process and Regulations in Malaysia 87
6.6 Registration Process and Regulations in Hong Kong 89
6.7 Registration Process and Regulations in Singapore 90
7 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Pipeline Analysis 92
7.1 Seasonal Influenza Vaccines – Promising Vaccines under Clinical Development 92
7.2 Profiles for Promising Vaccines under Clinical Development 93
7.2.1 Optaflu 93
7.2.2 GSK2186877A 93
7.2.3 Intanza / Flu-ID 94
7.2.4 Fluad Pediatric 95
7.3 Research and Development Pipeline 96
8 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Competitive Landscape 101
8.1 Major Seasonal Influenza Vaccines Marketed in the APAC Region 101
8.1.1 Fluarix 101
8.1.2 Vaxigrip 101
8.1.3 Influvac 101
8.1.4 Fluvax 101
8.1.5 Agrippal 101
8.2 Key Areas Focused for R&D 102
8.3 Competitive Profiling 103
8.3.1 Sanofi Pasteur 103
8.3.2 GlaxoSmithKline Biologicals 103
8.3.3 Abbott Laboratories (Solvay Pharmaceuticals) 103
8.3.4 CSL Biotherapies 103
8.3.5 Novartis Vaccines 104
8.3.6 Adimmune Corporation 104
8.3.7 Crucell N.V. (Berna Biotech) 104
9 Seasonal Influenza Vaccine Market in Asia-Pacific Region: M&A Landscape 105
9.1 Overview 105
9.1.1 AstraZeneca Acquires Medimmune 106
9.1.2 Sanofi Aventis Acquires Acambis 106
9.1.3 Mymetics Acquires Virosome Biologicals 106
9.1.4 Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock 106
9.1.5 Novartis to Acquire a Majority Stake in Zhejiang Tianyuan 106
9.1.6 Abbott Laboratories Acquires Solvay Pharmaceuticals 107
9.1.7 Nutri Pharma Acquires a Majority Stake in Bionor Immuno 107
9.1.8 Johnson & Johnson to Acquire a Majority Stake in Crucell 107
9.2 M&A Deals by Value 107
9.3 M&A Deals by Geography 108
9.4 R&D Licensing Agreements for the Period 2007-2010 108
9.4.1 Crucell Enters Into License Agreement With ADImmune 108
9.4.2 MedImmune Enters Into Licensing Agreement With Sanofi Pasteur 108
9.4.3 Vivalis Enters Into Licensing Agreement With GlaxoSmithKline 109
9.4.4 Vivalis Enters Into Licensing Agreement With Nobilon International 109
9.4.5 MedImmune Enters Into Licensing Agreement With GlaxoSmithKline 109
9.4.6 Hemispherx Biopharma Enters Into Licensing Agreement With BIKEN 109
9.4.7 MedImmune Enters Into Licensing Agreement With BIKEN 109
9.4.8 MedImmune Enters Into Licensing Agreement With Omninvest 109
9.4.9 OPKO Health Enters Into Licensing Agreement With Academia Sinica 110
9.4.10 AltraVax Enters Into Licensing Agreement With Maxygen 110
9.4.11 NasVax Announces Option Licensing Agreement With Novartis 110
9.4.12 iBio Enters Into Licensing Agreement With G-Con 110
9.4.13 Deals by Geography 111
10 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Appendix 112
10.1 Market Definitions 112
10.2 Abbreviations 112
10.3 Research Methodology 112
10.3.1 Coverage 112
10.3.2 Secondary Research 113
10.3.3 Primary Research 113
10.3.4 Expert Panel Validation 114
10.4 Contact Us 114
10.5 Disclaimer 114
10.6 Sources 114

1.1 List of Tables
Table 1: Seasonal Influenza Vaccine Market, APAC Region, Revenue ($m), 2009-2016 14
Table 2: Seasonal Influenza Vaccine Market, APAC Region, Country Wise Revenue ($m), 2009-2016 15
Table 3: Seasonal Influenza Vaccine Market, Australia, Vaccinated Population Contribution by Age Groups (%), 2009-2016 19
Table 4: Seasonal Influenza Vaccine Market, Australia, Overall Vaccination Coverage (Thousands), 2009-2016 19
Table 5: Seasonal Influenza Vaccine Market, Australia, Vaccination Coverage Break-up by Age Groups (Thousand), 2009-2016 19
Table 6: Seasonal Influenza Vaccine Market, Australia, Overall Number of Doses (Thousands), 2009-2016 20
Table 7: Seasonal Influenza Vaccine Market, Australia, Number of Doses by Age Groups, (Thousands), 2009-2016 21
Table 8: Seasonal Influenza Vaccine Market, Australia, Revenue ($m), 2009-2016 22
Table 9: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Contribution by Age Groups (%), 2009-2016 25
Table 10: Seasonal Influenza Vaccine Market, New Zealand, Overall Vaccination Coverage (Thousands), 2009-2016 26
Table 11: Seasonal Influenza Vaccine Market, New Zealand, Vaccination Coverage by Age Groups (Thousands), 2009-2016 26
Table 12: Seasonal Influenza Vaccine Market, New Zealand, Overall Number of Doses (Thousands), 2009-2016 26
Table 13: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses by Age Groups (Thousands), 2009-2016 27
Table 14: Seasonal Influenza Vaccine Market, New Zealand, Revenues ($000s), 2009-2016 28
Table 15: Seasonal Influenza Vaccine Market, Taiwan, Vaccinated Population Contribution by Age Groups (%), 2009-2016 32
Table 16: Seasonal Influenza Vaccine Market, Taiwan, Overall Vaccination Coverage (Thousands), 2009-2016 33
Table 17: Seasonal Influenza Vaccine Market, Taiwan, Vaccination Coverage by Age Groups (Thousands), 2009-2016 33
Table 18: Seasonal Influenza Vaccine Market, Taiwan, Overall Number of Doses (Thousands), 2009-2016 33
Table 19: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses by Age Groups (Thousands), 2009-2016 34
Table 20: Seasonal Influenza Vaccine Market, Taiwan, Revenues ($m), 2009-2016 36
Table 21: Seasonal Influenza Vaccine Market, Philippines, Vaccinated Population Contribution by Age Groups (%), 2009-2016 39
Table 22: Seasonal Influenza Vaccine Market, Philippines, Overall Vaccination Coverage (Thousands), 2009-2016 40
Table 23: Seasonal Influenza Vaccine Market, Philippines, Vaccination Coverage by Age Groups (Thousands), 2009-2016 40
Table 24: Seasonal Influenza Vaccine Market, Philippines, Overall Number of Doses (Thousands), 2009-2016 40
Table 25: Seasonal Influenza Vaccine Market, Philippines, Number of Doses by Age Groups (Thousands), 2009-2016 41
Table 26: Seasonal Influenza Vaccine Market, Philippines, Revenues ($m), 2009-2016 43
Table 27: Seasonal Influenza Vaccine Market, Malaysia, Vaccinated Population Contribution by Age Groups (%), 2009-2016 46
Table 28: Seasonal Influenza Vaccine Market, Malaysia, Overall Vaccination Coverage (Thousands), 2009-2016 47
Table 29: Seasonal Influenza Vaccine Market, Malaysia, Vaccination Coverage by Age Groups (Thousands), 2009-2016 47
Table 30: Seasonal Influenza Vaccine Market, Malaysia, Overall Number of Doses (Thousands), 2009-2016 47
Table 31: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses by Age Groups (Thousands), 2009-2016 48
Table 32: Seasonal Influenza Vaccine Market, Malaysia, Revenues ($m), 2009-2016 49
Table 33: Seasonal Influenza Vaccine Market, Hong Kong, Vaccinated Population Contribution by Age Groups (%), 2009-2016 53
Table 34: Seasonal Influenza Vaccine Market, Hong Kong, Overall Vaccination Coverage (Thousands), 2009-2016 54
Table 35: Seasonal Influenza Vaccine Market, Hong Kong, Vaccination Coverage by Age Groups (Thousands), 2009-2016 54
Table 36: Seasonal Influenza Vaccine Market, Hong Kong, Overall Number of Doses (Thousands), 2009-2016 54
Table 37: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses by Age Groups (Thousands), 2009-2016 55
Table 38: Seasonal Influenza Vaccine Market, Hong Kong, Revenues ($m), 2009-2016 56
Table 39: Seasonal Influenza Vaccine Market, Singapore, Vaccinated Population Contribution by Age Groups (%), 2009-2016 60
Table 40: Seasonal Influenza Vaccine Market, Singapore, Overall Vaccination Coverage (Thousands), 2009-2016 61
Table 41: Seasonal Influenza Vaccine Market, Singapore, Vaccination Coverage by Age Groups (Thousands), 2009-2016 61
Table 42: Seasonal Influenza Vaccine Market, Singapore, Overall Number of Doses (Thousands), 2009-2016 61
Table 43: Seasonal Influenza Vaccine Market, Singapore, Number of Doses by Age Groups (Thousands), 2009-2016 62
Table 44: Seasonal Influenza Vaccine Market, Singapore, Revenues ($m), 2009-2016 63
Table 45: Seasonal Influenza Vaccine Market, Most Promising Vaccines Under Clinical Development, 2010 92
Table 46: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Pipeline, Filed in the US, 2010 97
Table 47: Seasonal Influenza Vaccines, Asia-Pacific Region, Phase III Clinical Pipeline, 2010 98
Table 48: Seasonal Influenza Vaccines, Asia-Pacific Region, Phase II Clinical Pipeline, 2010 98
Table 49: Seasonal Influenza Vaccines, Asia-Pacific Region, Phase I Clinical Pipeline, 2010 99
Table 50: Seasonal Influenza Vaccines, Asia-Pacific Region, Pre-Clinical Pipeline, 2010 99
Table 51: Seasonal Influenza Vaccines, Asia-Pacific Region, Discovery Phase Pipeline 100
Table 52: Seasonal Influenza Vaccine Market, Asia-Pacific, Major M&A Deals, 2007-2010 105

1.2 List of Figures
Figure 1: Seasonal Influenza Vaccine Market, APAC Region, Revenue ($m), 2009-2016 14
Figure 2: Seasonal Influenza Vaccine Market, APAC Region, Country Wise Market Share (%), 2009 and 2016 15
Figure 3: Seasonal Influenza Vaccine Market, Australia, Population (Thousands), 2009-2016 17
Figure 4: Seasonal Influenza Vaccine Market, Australia, Vaccinated Population Contribution by Age Groups (%), 2009-2016 18
Figure 5: Seasonal Influenza Vaccine Market, Australia, Number of Doses by Age Groups, (Thousands), 2009-2016 20
Figure 6: Seasonal Influenza Vaccine Market, Australia, Revenue ($m), 2009-2016 22
Figure 7: Seasonal Influenza Vaccine Market, Australia, Break-up of Revenues ($m), 2009-2016 23
Figure 8: Seasonal Influenza Vaccine Market, New Zealand, Population (Thousands), 2009-2016 24
Figure 9: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Contribution by Age Groups (%), 2009-2016 25
Figure 10: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses by Age Groups (Thousands), 2009-2016 27
Figure 11: Seasonal Influenza Vaccine Market, New Zealand, Revenues ($m), 2009-2016 28
Figure 12: Seasonal Influenza Vaccine Market, New Zealand, Break-up of Revenues ($m), 2009-2016 29
Figure 13: Seasonal Influenza Vaccine Market, New Zealand, Market Share for Top Manufacturers, (%), 2009 30
Figure 14: Seasonal Influenza Vaccine Market, Taiwan, Population (Thousands), 2009-2016 31
Figure 15: Seasonal Influenza Vaccine Market, Taiwan, Vaccinated Population Contribution by Age Groups (%), 2009-2016 32
Figure 16: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses by Age Groups (Thousands), 2009-2016 34
Figure 17: Seasonal Influenza Vaccine Market, Taiwan, Revenues ($m), 2009-2016 35
Figure 18: Seasonal Influenza Vaccine Market, Taiwan, Break-up of Revenues ($m), 2009-2016 36
Figure 19: Seasonal Influenza Vaccine Market, Taiwan, Market Share for Top Manufacturers, (%), 2009 37
Figure 20: Seasonal Influenza Vaccine Market, Philippines, Population (Thousands), 2009-2016 38
Figure 21: Seasonal Influenza Vaccine Market, Philippines, Vaccinated Population Contribution by Age Groups (%), 2009-2016 39
Figure 22: Seasonal Influenza Vaccine Market, Philippines, Number of Doses by Age Groups (Thousands), 2009-2016 41
Figure 23: Seasonal Influenza Vaccine Market, Philippines, Revenues ($m), 2009-2016 42
Figure 24: Seasonal Influenza Vaccine Market, Philippines, Break-up of Revenues ($m), 2009-2016 43
Figure 25: Seasonal Influenza Vaccine Market, Philippines, Market Share for Top Manufacturers, (%), 2009 44
Figure 26: Seasonal Influenza Vaccine Market, Malaysia, Population (Thousands), 2009-2016 45
Figure 27: Seasonal Influenza Vaccine Market, Malaysia, Vaccinated Population Contribution by Age Groups (%), 2009-2016 46
Figure 28: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses by Age Groups (Thousands), 2009-2016 48
Figure 29: Seasonal Influenza Vaccine Market, Malaysia, Revenues ($m), 2009-2016 49
Figure 30: Seasonal Influenza Vaccine Market, Malaysia, Break-up of Revenues ($m), 2009-2016 50
Figure 31: Seasonal Influenza Vaccine Market, Malaysia, Market Share for Top Manufacturers, (%), 2009 51
Figure 32: Seasonal Influenza Vaccine Market, Hong Kong, Population (Thousands), 2009-2016 52
Figure 33: Seasonal Influenza Vaccine Market, Hong Kong, Vaccinated Population Contribution by Age Groups (%), 2009-2016 53
Figure 34: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses by Age Groups (Thousands), 2009-2016 55
Figure 35: Seasonal Influenza Vaccine Market, Hong Kong, Revenues ($m), 2009-2016 56
Figure 36: Seasonal Influenza Vaccine Market, Hong Kong, Break-up of Revenues ($m), 2009-2016 57
Figure 37: Seasonal Influenza Vaccine Market, Hong Kong, Market Share for Top Manufacturers, (%), 2009 58
Figure 38: Seasonal Influenza Vaccine Market, Singapore, Population (Thousands), 2009-2016 59
Figure 39: Seasonal Influenza Vaccine Market, Singapore, Vaccinated Population Contribution by Age Groups (%), 2009-2016 60
Figure 40: Seasonal Influenza Vaccine Market, Singapore, Number of Doses by Age Groups (Thousands), 2009-2016 62
Figure 41: Seasonal Influenza Vaccine Market, Singapore, Revenues ($m), 2009-2016 63
Figure 42: Seasonal Influenza Vaccine Market, Singapore, Break-up of Revenues ($m), 2009-2016 64
Figure 43: Seasonal Influenza Vaccine Market, Singapore, Market Share for Top Manufacturers, (%), 2009 65
Figure 44: Seasonal Influenza Vaccine Market, APAC Region, Drivers and Restraints, 2009-2016 66
Figure 45: Total Detections of Influenza Virus in APAC Countries during 2000-2010 67
Figure 46: Increase in Influenza Cases Due to H1N1 Pandemic Influenza in 2009 68
Figure 47: Increasing Vaccination Coverage Against Seasonal Influenza 69
Figure 48: Vaccination Coverage Rates Forecasts for APAC Region, (%), 2009-2016 70
Figure 49: Regulatory Authorities in Australia 77
Figure 50: Drug Approval Process in Australia 78
Figure 51: Regulatory Authorities in New Zealand 79
Figure 52: Drug Approval Process in New Zealand 80
Figure 53: Regulatory Authorities in Taiwan 83
Figure 54: Drug Approval Process in Taiwan 84
Figure 55: Regulatory Authorities in the Philippines 85
Figure 56: Drug Approval Process in Philippines 85
Figure 57: Regulatory Authorities in Malaysia 87
Figure 58: Drug Approval Process in Malaysia 88
Figure 59: Regulatory Authorities in Hong Kong 89
Figure 60: Drug Approval Process in Hong Kong 89
Figure 61: Regulatory Authorities in Singapore 90
Figure 62: Drug Approval Process in Singapore 90
Figure 63: Seasonal Influenza Vaccine Market, Asia-Pacific Region, R&D Pipeline by Phase (%), 2010 96
Figure 64: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Clinical Pipeline by Class of Vaccine (%), 2010 97
Figure 65: Seasonal Influenza Vaccine Market, Product Pipeline of Major Players in Asia-Pacific Region, 2010 102
Figure 66: Seasonal Influenza Vaccine Market, M&A Deals by Value, (%), 2007-2010 107
Figure 67: Seasonal Influenza Vaccine Market, M&A Deals by Geography, (%), 2007-2010 108
Figure 68: Seasonal Influenza Vaccine Market, Major R&D and Licensing Agreements by Geography, (%), 2007-2010 111

“Seasonal Influenza Vaccine Market in Asia-Pacific Region- Threat of Pandemic Influenza and Increasing Vaccination Coverage to Drive Growth” provides in-depth analysis of the drivers and barriers that affect the seasonal influenza vaccine market in Asia-Pacific region. The report analyzes the markets for seasonal influenza vaccine in Australia, New Zealand, Taiwan, Philippines, Malaysia, Hong Kong and Singapore. Vaccination patterns, sales, and price are forecast until 2016. Further, the report provides profiles for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the Asia-Pacific Seasonal Influenza Vaccine Market. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Seasonal Influenza Vaccine Market in the Asia-Pacific Region is Forecast to Show High Growth

Seasonal influenza vaccine market in the APAC Region is a fast growing market, due to increasing vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 13.3% during the period 2009-2016 from $219.7m in 2009 to $527m by 2016. The growth is driven by factors such as increasing awareness about influenza due to the threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies.

Seasonal Influenza Vaccine Market, APAC Region, Revenue ($m), 2009-2016

The authors found that the Philippines’ seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of volume and growth rate. The Philippines’ seasonal influenza vaccine market is forecast to grow from $57.3m in 2009 to $283.9m in 2016 at an impressive CAGR of 25.7%. Other attractive markets in terms of growth rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. These are forecast to grow at CAGRs of 27% and 22.1% respectively during 2009-2016. Australia’s seasonal influenza vaccine market is also a large sized attractive market forecast to grow at a CAGR of 4.1% during 2009-2016 from $80.8m in 2009 to $106.9m by 2016.

Customers who bought this item also bought

• Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants
• Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 - Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose
• Opportunity Analysis of H1N1 (swine flu) Vaccination Market
• Influenza Vaccines
• World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
• Epidemiology: Influenza - Incident cases expected to remain stable due to low vaccination rates
• Influenza Vaccines 2012
• China Vaccine Industry Report, 2009-2010
• China Vaccine Industry Report, 2009-2010
• Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth